Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LONDON, Ontario, March 27, 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. („Aduro“ oder das „Unternehmen“) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), ein Unternehmen für umweltfreundliche...
-
LONDON, Ontario, 27 mars 2026 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (ci-après « Aduro » ou la « Société ») (Nasdaq : ADUR) (CSE : ACT) (FSE : 9D5), une société de technologie propre qui...
-
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to...
-
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company...
-
SALT LAKE CITY, March 26, 2026 (GLOBE NEWSWIRE) -- Datacentrex, Inc. (Nasdaq: DTCX) (“Datacentrex” or the “Company”), a digital infrastructure and capital deployment company that owns and operates...
-
New York, NY, March 26, 2026 (GLOBE NEWSWIRE) -- QDRO Acquisition Corp. (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset...
-
Châtillon, France, le 26 mars 2026 DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 -...
-
Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –...
-
~ Mike Masci Named CFO; Brandon Alexandroff to Continue with Company as Strategic Advisor to CEO ~ ~ Newly Appointed CFO Brings Both Data Center Industry and Prior CFO Experience ~ LONGBOAT KEY,...
-
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer...